Scarica l'app Stockscreener
6.20
2.14%
0.13
Precedente Chiudi:
$6.07
Aprire:
$6.08
Volume 24 ore:
1.04M
Relative Volume:
0.58
Capitalizzazione di mercato:
$1.07B
Reddito:
$291.85M
Utile/perdita netta:
$554.00K
Rapporto P/E:
-815.79
EPS:
-0.0076
Flusso di cassa netto:
$27.93M
1 W Prestazione:
+4.73%
1M Prestazione:
+13.55%
6M Prestazione:
-33.12%
1 anno Prestazione:
+41.55%
Intervallo 1D:
$6.05
$6.22
Intervallo di 1 settimana:
$5.755
$6.22
Portata 52W:
$3.95
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Nome
Xeris Biopharma Holdings Inc
Settore
Industria
Telefono
844-445-5704
Indirizzo
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
6.20 | 1.05B | 291.85M | 554.00K | 27.93M | -0.0076 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-08-12 | Ripresa | H.C. Wainwright | Buy |
| 2024-11-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | Iniziato | Oppenheimer | Outperform |
| 2023-08-28 | Iniziato | Craig Hallum | Buy |
| 2022-10-21 | Iniziato | Jefferies | Buy |
| 2022-04-28 | Iniziato | Craig Hallum | Buy |
| 2021-11-17 | Iniziato | SVB Leerink | Outperform |
| 2021-10-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2020-02-18 | Iniziato | Piper Sandler | Overweight |
| 2018-07-16 | Iniziato | Jefferies | Buy |
| 2018-07-16 | Iniziato | Leerink Partners | Outperform |
| 2018-07-16 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Xeris Biopharma Holdings Inc Borsa (XERS) Ultime notizie
Record Profitability, 2026 Growth Outlook and Recorlev Patent Suit Might Change The Case For Investing In Xeris Biopharma Holdings (XERS) - Sahm
XERS.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Does Record Q4 Results, Robust 2026 Guidance and Recorlev Patent Suit Change The Bull Case For Xeris (XERS)? - Yahoo Finance
Barclays Initiates Coverage on Xeris Biopharma Holdings (XERS) w - GuruFocus
XERS.O Technical Analysis & Stock Price Forecast - Intellectia AI
Earnings Recap: Why is Xeris Biopharma Holdings Inc stock going upWeekly Stock Summary & Verified Short-Term Trading Plans - baoquankhu1.vn
Q1 2025 Xeris Biopharma Holdings Inc Earnings Call Transcript - GuruFocus
XERS Should I Buy - Intellectia AI
XERS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Q4 2025 Earnings Beat - Sahm
Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue? - MSN
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)April 3, 2026 - BioSpace
Oppenheimer Maintains Xeris Biopharma Holdings (XERS) Outperform Recommendation - MSN
XERS Technical Analysis & Stock Price Forecast - Intellectia AI
Xeris Biopharma (NASDAQ:XERS) Insider Sells $99,835.33 in Stock - MarketBeat
Beth Hecht Sells 16,667 Shares of Xeris Biopharma Holdings Inc (XERS) - GuruFocus
Xeris Biopharma Approves Inducement Grants for 50,000 Shares to Two New Employees - geneonline.com
Xeris Biopharma (XERS) officer sells 16,667 shares under 10b5-1 plan - Stock Titan
James Aloysius Brady Sells 10,834 Shares of Xeris Biopharma (NASDAQ:XERS) Stock - MarketBeat
Tudor Investment Corp ET AL Decreases Stake in Xeris Biopharma Holdings, Inc. $XERS - marketbeat.com
Insider Sell: James Brady Sells Shares of Xeris Biopharma Holdin - GuruFocus
Brady sells Xeris Biopharma (XERS) shares worth $60,035 By Investing.com - Investing.com Australia
Brady sells Xeris Biopharma (XERS) shares worth $60,035 - Investing.com
Xeris Biopharma (XERS) director sells 10,834 shares in Rule 10b5-1 trades - Stock Titan
XERS Stock Price, Quote & Chart | XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) - ChartMill
[144] Xeris Biopharma Holdings, Inc. SEC Filing - Stock Titan
Aug Macro: Will Xeris Biopharma Holdings Inc stock recover after earningsEntry Point & AI Enhanced Trading Alerts - baoquankhu1.vn
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Stock List: Research Stocks from Around the World - GuruFocus
Vanguard (XERS) disaggregates holdings after Jan 12, 2026 realignment; reports 0 shares - Stock Titan
Revenue per share of Xeris Biopharma Holdings, Inc. – LSE:0A8E - TradingView
Xeris Biopharma shares rise nearly 3% after Q4 earnings beat and strong 2026 outlook - MSN
Xeris Biopharma (NASDAQ:XERS) Shares Up 5.4%What's Next? - MarketBeat
Market Review: Can Xeris Biopharma Holdings Inc keep up with sector leaders - baoquankhu1.vn
Xeris Biopharma stock faces analyst scrutiny amid pipeline delays and biotech volatility - AD HOC NEWS
Barclays reiterates Xeris Pharmaceuticals stock rating on sales outlook By Investing.com - Investing.com Canada
350,168 Shares in Xeris Biopharma Holdings, Inc. $XERS Purchased by Granahan Investment Management LLC - MarketBeat
Xeris Biopharma (NASDAQ: XERS) officer boosts stake via option exercise - Stock Titan
Divisadero Street Capital Management LP Takes $3.31 Million Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma Holdings, Inc. $XERS Shares Sold by Rosalind Advisors Inc. - MarketBeat
Xeris Biopharma Holdings (XERS) Price Target Increased by 27.78% to 11.73 - MSN
Transcript : Xeris Biopharma Holdings, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 11 - marketscreener.com
XERS: RECORLEV's rapid growth and pipeline advances drive strong financial and strategic momentum - TradingView
Xeris Biopharma (XERS) Q4 2025 Earnings Transcript - AOL.com
Assessing Xeris Biopharma Holdings (XERS) Valuation After Profitability Milestone And 2026 Revenue Guidance - simplywall.st
XERS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Xeris Pharmaceuticals Q2 2025 Earnings Preview - MSN
Xeris Biopharma Holdings Inc Azioni (XERS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):